{"id":"NCT02736409","sponsor":"Shire","briefTitle":"An Extension Study to Evaluate Maintenance of Efficacy and Long-term Treatment Effect of Oral Budesonide Suspension (OBS) in Adults and Adolescents With Eosinophilic Esophagitis (EoE)","officialTitle":"A Phase 3, Multicenter, Double-blind Extension Study to Evaluate Maintenance of Efficacy of Oral Budesonide Suspension (OBS) and Long-term Treatment Effect of OBS in Adolescent and Adult Subjects (11 to 55 Years of Age, Inclusive) With Eosinophilic Esophagitis (EoE)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-04-01","primaryCompletion":"2019-11-12","completion":"2019-11-12","firstPosted":"2016-04-13","resultsPosted":"2021-01-13","lastUpdate":"2025-02-19"},"enrollment":219,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Eosinophilic Esophagitis (EoE)"],"interventions":[{"type":"DRUG","name":"Oral Budesonide Suspension (OBS)","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Arms A OBS Completers/ Responders","type":"EXPERIMENTAL"},{"label":"Arm B OBS Completers/ Responders","type":"PLACEBO_COMPARATOR"},{"label":"Arm C OBS Completers/ Non-Responders","type":"EXPERIMENTAL"},{"label":"Arm D Placebo Completers","type":"EXPERIMENTAL"}],"summary":"This is a multicenter, double- blind extension study of Oral Budesonide Suspension (OBS) in adults and adolescents (11 to 55 years of age, inclusive) with Eosinophilic Esophagitis (EoE) who have completed participation in the SHP621-301 induction study (NCT02605837). The primary objective is to evaluate the maintenance of efficacy of OBS over 36 weeks. Maintenance of efficacy will be measured by the peak eosinophilic count and Dysphagia Symptom Questionnaire (DSQ) score.","primaryOutcome":{"measure":"Proportion of Participants Who Had Relapse During the Entire Week 36 Period","timeFrame":"Week 36","effectByArm":[{"arm":"Full Responder BOS-PBO Group","deltaMin":0.43,"sd":null},{"arm":"Full Responder BOS-BOS Group","deltaMin":0.24,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.131"}]},"eligibility":{"minAge":"11 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":62,"countries":["United States"]},"refs":{"pmids":["39735351","34182150"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":23},"commonTop":["Nausea","Upper respiratory tract infection","Vomiting","Nasopharyngitis","Diarrhoea"]}}